2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05281484 (ClinicalTrials.gov) | August 31, 2022 | 7/3/2022 | Intermediate Expanded Access Protocol (EAP) CNMAu8.EAP02 | A Second Intermediate Expanded Access Protocol for Amyotrophic Lateral Sclerosis With CNM-Au8 | Amyotrophic Lateral Sclerosis | Drug: CNM-Au8 | Clene Nanomedicine | NULL | Available | 18 Years | N/A | All | United States | ||
2 | NCT05299658 (ClinicalTrials.gov) | November 13, 2021 | 8/3/2022 | An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS | An Open-Label Extension for the Phase 2, Randomised, Double-Blind, Placebo-Controlled Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS | Amyotrophic Lateral Sclerosis | Drug: CNMAu8 | Clene Nanomedicine | NULL | Active, not recruiting | 30 Years | 80 Years | All | 40 | Phase 2 | Australia |